Aemetis (AMTX) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
8 Jul, 2026Executive summary
Q1 2025 revenues were $42.9 million, down from $72.6 million year-over-year due to delayed India biodiesel contracts and OMC sales pause; shipments resumed in April with new $31 million OMC letters of intent received.
Net loss was $24.5 million, similar to Q1 2024, as operating loss widened to $15.6 million; cash at quarter-end was $0.5 million after debt repayment and investments.
California Ethanol segment saw modest revenue growth and surpassed $2 billion in cumulative revenue; Dairy RNG and India Biodiesel segments declined sharply.
Multiple revenue streams, including India, LCFS credits, and federal tax incentives, are expected to ramp up in the second half of 2025.
Company continues to invest in energy efficiency, RNG expansion, and new projects like SAF/RD and carbon capture.
Financial highlights
Revenues declined primarily due to a pause in India biodiesel shipments, which have now resumed; Q1 2025 revenue was $42.9 million, down from $72.6 million in Q1 2024.
Gross loss widened to $5.1 million from $0.6 million year-over-year; operating loss increased to $15.6 million from $9.5 million.
Adjusted EBITDA was $(10.7) million, down from $(4.8) million in Q1 2024.
SG&A expenses increased by $1.6 million, mainly from legal and transaction costs tied to $19 million in investment tax credit sales.
Interest expense rose to $13.7 million, reflecting the current capital structure.
Outlook and guidance
Significant ramp in RNG revenues expected in Q3 2025 as LCFS pathway approvals and volume growth materialize.
India Biodiesel segment anticipates substantial sales in upcoming quarters due to new OMC contracts and resumed shipments.
Ethanol margins to benefit from policy tailwinds and cost reductions from the MVR project starting in 2026.
Monetization of tax credits and development of SAF and carbon capture projects to support growth and cash flow through 2026.
Company plans to continue equity sales, seek new debt, and pursue project-specific financing.
Latest events from Aemetis
- Q3 2024 revenue up 18.6–19% to $81.4M, but net loss and liquidity risks remain.AMTX
Q3 20248 Jul 2026 - Revenue up 43% to $268M, but net loss widened to $87.5M; policy and tax credits to boost growth.AMTX
Q4 20248 Jul 2026 - Revenue up 27% to $54.6M, gross profit positive, but high debt clouds outlook.AMTX
Q1 202613 May 2026 - Proxy seeks votes on director election and auditor ratification, with emphasis on governance and compensation.AMTX
Proxy filing7 Apr 2026 - Dairy RNG output soared, losses narrowed, and investments and policy wins set up 2026 growth.AMTX
Q4 202512 Mar 2026 - Q2 revenue up 48% to $66.6M, but net loss widened and liquidity concerns persist.AMTX
Q2 20242 Feb 2026 - Board approves executive bonuses, $80M share buyback, and charter amendments for share structure.AMTX
Proxy Filing28 Jan 2026 - Stockholders to vote on key changes to capital structure and meeting procedures, with Board support.AMTX
Proxy Filing31 Dec 2025 - Votes sought to amend capital structure and empower Board for future growth and flexibility.AMTX
Proxy Filing19 Dec 2025